Financial Performance - The company reported a revenue of HKD 104,163,000 for the year ending December 31, 2025, representing a 12.5% increase from HKD 92,605,000 in 2024[3] - Gross profit increased to HKD 16,927,000, up 58.8% from HKD 10,654,000 in the previous year[3] - The operating loss decreased significantly to HKD 13,228,000 from HKD 43,481,000, indicating improved operational efficiency[3] - The net loss for the year was HKD 13,333,000, a reduction of 69.5% compared to HKD 43,641,000 in 2024[3] - The group generated revenue of HKD 104,163,000 in 2025, an increase of 12.5% from HKD 92,605,000 in 2024[16] - Revenue from TFT-LCD panels and modules reached HKD 82,493,000 in 2025, up 105.5% from HKD 40,161,000 in 2024[16] - The group reported a net loss before tax of HKD 881,000 in 2025, a significant improvement compared to a loss of HKD 18,818,000 in 2024[21] - The loss attributable to equity holders of the company was approximately HKD 12,492,000, a reduction of about 71% from HKD 42,906,000 in the previous year[36] - The group's total revenue for the year was approximately HKD 104,163,000, an increase of about 12% compared to approximately HKD 92,605,000 in 2024, primarily driven by increased sales of TFT-LCD panels and modules[41] - The group's gross profit for the year was approximately HKD 16,927,000, representing a 59% increase from approximately HKD 10,654,000 in 2024, attributed to higher revenue and improved gross margins on TFT-LCD panels and modules[43] - The group's net loss attributable to equity holders for the year was approximately HKD 12,492,000, a reduction of about 71% compared to a loss of approximately HKD 42,906,000 in 2024, mainly due to increased revenue and effective cost control measures[49] Liquidity and Financial Position - The company's cash and cash equivalents decreased to HKD 18,244,000 from HKD 24,407,000, reflecting ongoing liquidity challenges[4] - Total assets decreased to HKD 44,292,000 from HKD 58,357,000, indicating a decline in overall financial position[4] - The net current assets were HKD 26,833,000, a decrease from HKD 41,117,000 in 2024, highlighting ongoing financial pressures[9] - The group’s cash and cash equivalents as of December 31, 2025, were approximately HKD 18,244,000, down from HKD 24,407,000 in 2024[50] - The fair value of financial assets at fair value through profit or loss decreased to HKD 9,911,000 from HKD 16,641,000 in the previous year[30] - The company recorded a net cash outflow from operating activities of HKD 11,833,000, down from HKD 18,014,000 in the previous year[9] - The company did not declare any dividends for the year, consistent with the previous year[27] - The net cash outflow from operating activities was HKD 11,833,000, raising concerns about the company's ability to continue as a going concern[34] Cost Management - Cost control measures will be actively implemented, including adjustments to human resources, to enhance financial stability[10] - The group's total sales cost for the year was approximately HKD 87,236,000, an increase of about 6% from approximately HKD 81,951,000 in 2024, primarily due to increased procurement costs related to TFT-LCD panels and modules[42] - The group's distribution and selling expenses were approximately HKD 9,479,000, a decrease of about 24% from approximately HKD 12,533,000 in 2024, primarily due to reduced promotional expenses for health-related products[45] - The group's research and development expenses were approximately HKD 792,000, a decrease of about 35% from approximately HKD 1,227,000 in 2024, due to reduced employee costs[47] Strategic Initiatives - The company plans to continue selling financial assets valued at HKD 9,911,000 to improve liquidity[9] - The group plans to implement measures to improve sales and generate operating cash flow, while avoiding major capital expenditure in the near term[13] - The group aims to enhance operational cash flow and working capital status through various measures[13] - The group plans to continue exploring opportunities in the electric vehicle charging infrastructure sector, aiming to enhance its diversified business portfolio[38] Governance and Compliance - The company is involved in ongoing legal proceedings related to allegations of director misconduct regarding the sale of approximately 50.14% of its stake in a subsidiary[59] - The company has adopted the principles and code provisions of the Corporate Governance Code as per GEM Listing Rules Appendix C1[60] - The audit committee, established on January 20, 2014, consists of three independent non-executive directors and has reviewed the annual performance of the group[62] - The auditors, PwC, confirmed that the financial figures in the preliminary results announcement align with the audited financial statements for the year ending December 31, 2025[63] Shareholder Information - The annual general meeting is scheduled for June 17, 2026, with a record date for voting rights set for June 17, 2026[64] - The company will suspend share transfer registration from June 12, 2026, to June 17, 2026, to determine attendance rights at the annual general meeting[65] - The board currently includes four executive directors, three of whom have suspended their duties, and three independent non-executive directors[66] - The company did not repurchase any shares during the year, nor did it buy or sell any of its own shares[57]

Financial Performance - For the year ended December 31, 2025, the company reported revenue of RMB 168.3 million, representing a 3.2% increase from RMB 163.1 million in 2024[4] - Gross profit for 2025 was RMB 88.1 million, a significant increase of 120.3% compared to RMB 40.0 million in 2024[4] - The company reduced its loss before tax to RMB 90.4 million, a 60.9% improvement from a loss of RMB 231.1 million in the previous year[4] - Net loss for the year was RMB 118.8 million, down 48.3% from RMB 230.0 million in 2024[4] - Basic and diluted loss per share improved to RMB 0.30 from RMB 0.58 in 2024[5] - The company reported a total comprehensive loss of RMB 129.6 million for 2025, compared to RMB 221.5 million in 2024[6] - The company reported a pre-tax loss of RMB 118,153,000 for 2025, a decrease from a loss of RMB 232,541,000 in 2024, indicating an improvement in financial performance[26] - The net loss is projected to decrease from RMB 230.0 million in 2024 to RMB 118.8 million in 2025[75] Assets and Liabilities - Total assets decreased to RMB 2,533.4 million from RMB 2,673.1 million in 2024, reflecting a reduction in non-current assets[7] - Current assets totaled RMB 636.3 million, down from RMB 711.3 million in 2024, primarily due to a decrease in trade receivables[7] - Non-current liabilities decreased to RMB 16.6 million from RMB 25.4 million in 2024, indicating improved financial stability[8] - The company's equity decreased to RMB 2,516.8 million from RMB 2,647.6 million in 2024, reflecting the impact of the net loss[8] - Trade receivables decreased to RMB 390,998,000 in 2025 from RMB 434,344,000 in 2024, a decline of 10%[27] - Trade payables decreased from RMB 117,117,000 in 2024 to RMB 73,863,000 in 2025, indicating a significant reduction in liabilities[34] - The asset-liability ratio was 0.12% as of December 31, 2025, down from 0.26% in 2024, reflecting a conservative financial management strategy with no borrowings[99] Revenue Breakdown - Revenue from the mainland China market was RMB 111,141,000 in 2025, up from RMB 102,283,000 in 2024, representing an increase of 8.5%[17] - Revenue from variety show IP production, operation, and licensing increased by 15.3% to RMB 39.1 million in 2025, compared to RMB 33.9 million in 2024[49] - Revenue from music IP operation and licensing surged by 125.0% to approximately RMB 31.5 million in 2025, up from about RMB 14.0 million in 2024, mainly due to increased licensing renewals[50] - Revenue from other IP-related businesses decreased by 35.0% to approximately RMB 35.5 million in 2025, down from about RMB 54.6 million in 2024, due to contract expirations with several signed artists[52] Cost Management - The cost of production and operation for variety show IP was RMB 14,425,000 in 2025, significantly reduced from RMB 56,918,000 in 2024, reflecting a decrease of 74.6%[21] - The cost of sales decreased from RMB 123.1 million in 2024 to RMB 80.2 million in 2025, reflecting a reduction in production costs for variety shows[53] - Administrative expenses are forecasted to decrease by 45.1% from RMB 90.4 million in 2024 to approximately RMB 49.6 million in 2025, mainly due to a reduction in staff costs and depreciation expenses[65] Impairment and Provisions - The company’s impairment loss on trade and other receivables was RMB 14,022,000 in 2025, down from RMB 50,200,000 in 2024, indicating improved credit management[21] - The company recorded an impairment loss on goodwill of RMB 3.0 million in 2025, significantly lower than the RMB 48.5 million recorded in 2024, primarily due to anticipated decreases in future licensing income[66] - Provisions for various lawsuits totaled RMB 5,281,000 as of December 31, 2025, reflecting adjustments made during the year[35] Corporate Governance - The company has adopted the principles and provisions of the Corporate Governance Code as the basis for its corporate governance practices[109] - The board of directors has not recommended the payment of a final dividend for the year ending December 31, 2025, consistent with the previous year[116] - The company has established an audit committee consisting of three members, with an independent non-executive director serving as the chairman[113] - The company has established a nomination committee and a remuneration committee in addition to the audit committee[114] Future Plans and Strategy - The company aims to enhance its IP creation and operation capabilities, focusing on integrating AI technology into content creation, with plans to develop an interactive movie game and an AI comic series by mid-2026[41] - The company plans to expand its audience reach and brand influence by increasing partnerships with TV platforms, online video platforms, and music service providers[44] - The company is actively exploring new fields such as short dramas, comic series, and interactive games, while also integrating short videos with e-commerce and social platforms[45] - The company believes in the long-term growth potential of the Chinese entertainment IP industry despite market challenges, maintaining a stable performance in sales and market presence[42] Joint Ventures and Loans - The company provided three additional unsecured loans to CMC Asia totaling $2,050,000, with an interest rate of 5% and a repayment period of one year[31] - The company extended a loan of HKD 28,000,000 (approximately RMB 25,485,600) to CMC Asia, which was unsecured and interest-free, with a remaining balance of RMB 16,770,000 after partial settlement[33] - The company entered into a joint venture agreement to develop AI music business in China, with registered capital of RMB 1 million, and further investments planned totaling RMB 358.68 million[100] Employee and Talent Management - Employee compensation expenses totaled RMB 38.2 million in 2025, including director remuneration, with a total of 116 employees as of December 31, 2025[105] - The company is committed to attracting top talent in IP production, operation, and management through competitive compensation and training programs[44]

Financial Performance - The company achieved a sales revenue of RMB 1,213.3 million, representing a year-on-year growth of 46.3%[3] - The overall gross margin improved significantly from -19.5% in the previous year to +7.3%, an increase of 26.8%[3] - The company's total revenue for 2025 reached RMB 1,213.3 million, a 46.4% increase from RMB 828.5 million in 2024, driven by breakthroughs in GaN product applications across multiple sectors[33] - The sales cost for 2025 was RMB 1,124.5 million, up 13.6% from RMB 989.9 million in 2024, attributed to increased sales revenue while unit costs decreased[34] - The gross profit for 2025 was RMB 88.8 million, a turnaround from a gross loss of RMB 161.4 million in 2024, with a gross margin improvement from -19.5% to 7.3%[35] - Other net income for 2025 was RMB 113.1 million, a 56.6% increase from RMB 72.2 million in 2024, mainly due to increased government subsidies and bank interest income[36] - Revenue for the year ended December 31, 2025, was RMB 1,213,273 thousand, an increase of 46.5% compared to RMB 828,459 thousand in 2024[59] - The company reported a loss attributable to equity shareholders of RMB 840,513 thousand in 2025, an improvement from RMB 1,045,677 thousand in 2024[59] Product Development and Sales - Sales revenue from GaN chips in the AI and data center sector reached RMB 63.19 million, a year-on-year increase of 50.20%[7] - The shipment volume of automotive-grade GaN chips doubled year-on-year, with sales revenue reaching RMB 57.90 million[7] - The company launched 87 new products during the reporting period, with customer adoption of 1,182 projects, delivering over 800 million GaN chips[13] - In the industrial and energy storage sector, sales revenue reached RMB 520.51 million, an increase of 137.93% year-on-year[14] - The revenue from consumer electronics products was RMB 568.1 million, with a steady increase in market share[11] - IC product revenue saw a significant year-on-year increase of 513%, enhancing system efficiency and power density[12] - Revenue from the sale of GaN discrete devices and integrated circuits increased by 41.3% to RMB 510.1 million in 2025, driven by expanding applications in electric vehicles, data centers, and industrial sectors[38] - Revenue from GaN modules surged by 142.6% to RMB 446.2 million in 2025, attributed to the launch of a new generation of modules with enhanced technical and cost advantages[38] Research and Development - The company has achieved significant breakthroughs in product development, with over 70 new products launched and a stable yield rate of over 90% on its high and low voltage 3.0 process platform[17] - R&D expenses for 2025 were RMB 374.2 million, a 15.9% increase from RMB 323.0 million in 2024, reflecting ongoing expansion in research and development investments[40] - The company has confirmed compliance with corporate governance codes and standards during the reporting period[101][102] - The audit committee has confirmed compliance with applicable accounting principles and standards for the financial year ending December 31, 2025[111] Market Position and Strategy - The company has positioned itself as a leader in the global GaN power semiconductor market, driven by the increasing demand for high-efficiency, compact power devices in various sectors[16] - The company has become a core supplier for multiple AI server manufacturers, with 650V products achieving mass production for key domestic data center clients[22] - The company has successfully shipped over 6 million vehicle LiDAR units, enabling more than 1.5 million smart assisted driving vehicles[23] - The company has established strategic partnerships in the automotive sector, launching GaN vehicle chargers to enhance power density and efficiency[23] - The company has expanded its GaN chip applications in the energy storage sector, achieving mass production for battery protection BMS solutions and micro-inverter products[24] Financial Position and Liabilities - The group's net loss for 2025 was RMB 840.5 million, a reduction of 19.6% compared to a loss of RMB 1,045.7 million in the previous year, attributed to significant improvement in gross profit and stable operating expenses[42] - As of December 31, 2025, the group's cash and cash equivalents amounted to RMB 879.0 million, down from RMB 1,525.0 million as of December 31, 2024[43] - The total loans and borrowings of the group as of December 31, 2025, were RMB 2,229.7 million, an increase of RMB 305.8 million from RMB 1,923.9 million as of December 31, 2024, mainly to support production scale expansion[44] - The current ratio increased from 2.5 times as of December 31, 2024, to 5.3 times as of December 31, 2025, due to increased funds from placements and expanded sales scale[46] - The net debt ratio rose from 13.4% as of December 31, 2024, to 32.1% as of December 31, 2025, primarily due to a decrease in cash and an increase in total borrowings[48] Employee and Operational Metrics - As of December 31, 2025, the group employed 1,359 staff, with a focus on recruitment, training, and internal recommendations to enhance employee skills and knowledge[58] - Total employee costs increased to RMB 637,396,000 in 2025, up from RMB 590,715,000 in 2024, reflecting an 8% rise[79] Capital Expenditure and Investments - The group's capital expenditure for the year ended December 31, 2025, was RMB 210.6 million, an increase of RMB 38.8 million from RMB 171.8 million for the year ended December 31, 2024, mainly due to increased purchases of expansion equipment[53] - The company plans to increase wafer production capacity from 20,000 pieces per month, aiming to continuously optimize processes and improve yield rates[31] - The company plans to use the remaining unutilized funds by December 31, 2028, for the specified purposes[109] Shareholder and Dividend Information - The company did not declare or pay any dividends during the year[92] - The board of directors has decided not to recommend a final dividend for the year ending December 31, 2025[99] - The issued and fully paid ordinary shares increased to 915,100,000 as of December 31, 2025, from 879,152,000 in 2024, marking a growth of 4%[92] Compliance and Governance - The company has confirmed compliance with corporate governance codes and standards during the reporting period[101][102] - The audit committee has confirmed compliance with applicable accounting principles and standards for the financial year ending December 31, 2025[111] - The company's financial statements have been verified by KPMG, ensuring consistency with the audited financial reports[112]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 截至2025年12月31日止年度 全年業績公告 大成生化科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公告本公司及其附屬 公司（統稱「本集團」）截至2025年12月31日止年度（「本年度」）的綜合業績連同去年的比較 數字如下： 綜合損益及其他全面收益表 截至2025年12月31日止年度 | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收益 | 4 | 2,278,532 | 2,001,095 | | 銷售成本 | | (2,082,091) | (1,810 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 截至2025年12月31日止年度的年度業績公告 財務摘要 於報告期間： 日照港裕廊股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公 司截至2025年12月31日止年度（「報告期間」）的經審核財務業績（「全年業績」）， 連同截至2024年12月31日止年度的比較數字。全年業績已由本公司審計委員會 （「審計委員會」）審閱。 1 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6117) • 本公司的收入為人民幣664,773千元，較去年同期減少21.56%； • 股東應佔溢利淨額為人民幣170,946千元，較去年同期減少17.03%； • 本公司每股盈利為人民幣10.30分；及 • 董事會建議向股東派付末期股息每股人民幣0.030元（含稅）。 損益及其他全面收益表 | | 附註 | 2025年 | 2024年 | | --- | --- | --- | --- | | | | ...

Financial Performance - For the fiscal year 2025, the Group recorded a revenue of approximately S$13,067,000, representing a 43.8% decrease compared to S$23,255,000 in fiscal year 2024[21]. - The gross profit for FY2025 was approximately S$71,000, reflecting a 98.2% decrease from S$4,007,000 in FY2024[21]. - The loss after tax increased to approximately S$3,658,000 in FY2025, compared to a loss of approximately S$1,084,000 in FY2024[21]. - The decline in gross profit was the main contributor to the increased loss after tax for FY2025[22]. - The loss before tax for FY2025 was approximately S$3,328,000, compared to a loss of S$729,000 for FY2024[66]. - The Group's revenue from construction services for FY2025 was approximately S$13,067,000, a decrease from S$23,255,000 in FY2024[65]. - The Group reported a pre-tax loss of approximately S$3.33 million for the fiscal year 2025, compared to a pre-tax loss of S$729,000 for the fiscal year 2024[73]. Operational Insights - Selling and administrative expenses for FY2025 were approximately S$4,048,000, down from approximately S$5,622,000 in FY2024[35][40]. - The Group's liquidity risk is managed by actively monitoring customer credit limits and cash flows to ensure adequate working capital[37]. - The Group is actively seeking projects from other clients to mitigate customer concentration risk and enhance existing capacity to meet increasing demand[72]. - The Group plans to expand its market position in the structural steelwork industry in Singapore and explore the silver economy business in China and the Asia Pacific region[30][31]. - The Group is focusing on expanding its market position in the structural steel work industry in Singapore to accommodate increased demand from infrastructure projects[66][67]. - The Group is venturing into the China silver economy market by distributing healthy specialty products, aligning with its long-term growth strategy[70]. Market Outlook - The Singapore Building and Construction Authority projects total construction demand to remain steady at S$47-53 billion in nominal terms for 2026, similar to 2025[24]. - Total construction demand in Singapore for 2026 is projected to range between S$47 billion and S$53 billion, similar to 2025, with medium-term demand expected to improve steadily[77]. - The medium-term construction demand outlook is supported by a strong pipeline of large developments, including the redevelopment of NUH and the new SUSS City Campus[78]. - The construction industry in Singapore is expected to be driven by significant infrastructure projects, which will continue for the next decade[73]. Management and Governance - The Company has a diverse management team with expertise spanning agriculture, finance, technology, and corporate governance[97][91][99][100][101][102]. - The Company is focused on expanding its operations and enhancing its strategic planning capabilities through experienced leadership[101][102]. - The Board of Directors consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors[123][128]. - The Company has complied with the Corporate Governance Code during the year ended December 31, 2025, ensuring effective oversight of management[115][120]. - The Company emphasizes a healthy corporate culture, focusing on objectivity, transparency, and ethical conduct in decision-making[109][114]. - The Company has established a code of conduct for directors' securities transactions, ensuring compliance with GEM Listing Rules[122][127]. Internal Controls and Risk Management - The Group engaged an internal control consultant to perform an independent review of the risk management and internal control system for the financial year ended 31 December 2025[193]. - The internal control report was reviewed by the Board, which confirmed the effectiveness and adequacy of the Group's risk management and internal control systems[195]. - The Group's internal control system is designed to provide reasonable assurance against material misstatement or loss and to manage risks rather than eliminate them[191]. - The board regularly reviews and assesses the effectiveness of the internal control system, covering financial, operational, compliance, and risk management monitoring[197]. - A whistleblower policy has been established, encouraging stakeholders to report unethical acts, including bribery and corruption, to the company's registered office or via email[200]. Board Diversity and Appointments - As of December 31, 2025, the gender diversity ratio in the workforce is 14.8% female and 85.2% male[137]. - The Company has a board diversity policy that emphasizes a balance of skills, experience, and perspectives among board members[139]. - The nomination committee seeks individuals with high integrity and diverse perspectives for board appointments[146]. - All directors are subject to retirement by rotation at least once every three years, ensuring regular re-election opportunities[145]. - The Audit Committee consists of three independent non-executive Directors, with Mr. Wong Carson Ka Chun serving as the chairman, ensuring compliance with Rule 5.28 of the GEM Listing Rules[161]. Remuneration and Meetings - The Remuneration Committee held two meetings during the year to approve the remuneration of Directors and senior management[173]. - The attendance of the Remuneration Committee members was 100% for the meetings held, with all members present at both meetings[177]. - The Nomination Committee also held two meetings to review the Board's structure, size, and composition, and to assess the independence of independent non-executive Directors[181]. - The Board held three meetings during the year ended December 31, 2025, with full attendance from several directors[136].

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 189,411,000, a decrease of 4.9% from RMB 199,342,000 in 2024[4] - Gross profit increased to RMB 77,711,000, up 8.9% from RMB 71,407,000 in the previous year[4] - The company reported a net loss of RMB 2,197,000 for the year, significantly improved from a loss of RMB 63,263,000 in 2024[4] - Basic and diluted earnings per share for the year were RMB 0.34, compared to a loss of RMB 11.11 per share in 2024[4] - The company reported a total loss before tax of RMB 65,257,000 for the year ending December 31, 2024, with significant contributions from unallocated expenses of RMB 25,798,000 and financial costs of RMB 584,000[23] - The pre-tax profit for 2025 was RMB 10,000, a recovery from a loss of RMB 65,257,000 in 2024[30] - The company reported a net profit of approximately RMB 1.9 million for 2025, compared to a net loss of approximately RMB 59.2 million in 2024, indicating a turnaround from loss to profit[39] - The total comprehensive loss for 2025 was approximately RMB 2.2 million, a significant improvement from a loss of RMB 63.3 million in 2024[76] Revenue Breakdown - For the year ending December 31, 2025, total revenue reached RMB 189,411,000, with medical beauty services contributing RMB 152,909,000, medical beauty equipment RMB 32,832,000, and consulting services RMB 3,670,000[24] - Revenue for the year ended December 31, 2025, was RMB 189,411 thousand, a decrease of 5.0% compared to RMB 199,342 thousand in 2024[49] - Revenue from medical beauty services in 2025 was approximately RMB 152.9 million, an increase of about 7.6% from RMB 142.1 million in 2024[60] - Revenue from minimally invasive beauty services in 2025 was approximately RMB 84.5 million, up about 23.4% from RMB 68.5 million in 2024, driven by an increase in active customers and average spending[60] - Revenue from skin beauty services in 2025 was approximately RMB 62.3 million, a decrease of about 8.4% from RMB 68.1 million in 2024, primarily due to a reduction in active customers[60] - Revenue from cosmetic surgery services in 2025 was approximately RMB 4.8 million, an increase from RMB 4.1 million in 2024[60] Expenses and Costs - Research and development expenses rose to RMB 2,070,000, an increase from RMB 717,000 in the previous year[4] - The cost of supplies consumed decreased to RMB 61,290,000 in 2025 from RMB 65,611,000 in 2024, suggesting improved cost efficiency[27] - Sales and distribution expenses in 2025 were approximately RMB 37.8 million, down about 20.8% from RMB 47.7 million in 2024, attributed to reduced market investments[72] - Administrative expenses decreased by approximately 25.1% to RMB 31.3 million in 2025, primarily due to a reduction in share-based payment expenses and intermediary service costs[73] - The financial cost for 2025 was approximately RMB 2.7 million, slightly down from RMB 2.8 million in 2024[74] Assets and Liabilities - Cash and cash equivalents increased to RMB 57,793,000, up from RMB 28,870,000 in 2024[5] - Total current liabilities amounted to RMB 125,755,000, slightly up from RMB 123,588,000 in 2024[5] - Non-current liabilities decreased significantly to RMB 13,638,000 from RMB 30,817,000 in the previous year[6] - The company's total assets less current liabilities stood at RMB 111,896,000, down from RMB 126,335,000 in 2024[5] - The company maintained a net asset value of RMB 98,258,000, an increase from RMB 95,518,000 in 2024[6] - The total liabilities as of December 31, 2025, were approximately RMB 139.4 million, down from RMB 154.4 million in 2024, resulting in a debt-to-equity ratio of approximately 141.8%[86] Shareholder Information - The company did not declare or pay any dividends for the year ended December 31, 2025[32] - The board has decided not to declare any final dividend for the fiscal year 2025, consistent with the previous year[106] - The average number of ordinary shares outstanding increased to 557,077,333 in 2025 from 532,837,181 in 2024, which may impact earnings per share calculations[33] Regulatory and Compliance - International Financial Reporting Standard (IFRS) 18 introduces new presentation requirements for income statements, categorizing all income and expenses into five categories: operating, investing, financing, income tax, and discontinued operations[11] - The amendments to IFRS 9 and IFRS 7 are expected to have no significant impact on the group's financial statements[14][15][16] - The company has established an audit committee to oversee financial reporting processes and compliance with legal regulations[112] - The company has adopted the corporate governance code to ensure transparency, accountability, and independence[109] Strategic Initiatives - The company plans to enhance the capacity of non-surgical medical beauty services, focusing on the introduction of new technologies and equipment to meet consumer demand[42] - The company aims to launch more products and services tailored to different skin types and age groups to meet personalized consumer needs[42] - The company is optimizing its sales channels by leveraging internet platforms, social media, and partnerships with third-party platforms to enhance market reach and operational efficiency[45] - The company plans to focus on the sales of non-surgical medical beauty devices, increasing investment in technology and research, and expanding the geographical coverage of medical beauty service institutions[105] Market Conditions - The medical beauty industry in China is still in a phase of expansion and adjustment, with non-surgical beauty services being the main growth driver, particularly anti-aging projects[105] - The company faces risks including medical liability insurance, brand recognition, and exchange rate fluctuations affecting its operations[53]

Financial Performance - For the year ending December 31, 2025, the revenue increased by 7.1% to approximately RMB 823.5 million from RMB 768.9 million in 2024[5]. - The gross profit decreased by 2.9% to approximately RMB 407.5 million, resulting in a gross margin of 49.5%[7]. - The profit attributable to the company's owners fell by 37.4% to approximately RMB 94.4 million, down from RMB 150.8 million in 2024[5]. - The adjusted net profit (non-HKFRS measure) decreased by 15.4% to approximately RMB 197.6 million from RMB 233.5 million in 2024[5]. - The basic and diluted earnings per share for 2025 were RMB 6.25, a decrease of 36.0% compared to RMB 9.77 in 2024[5]. - The company's operating profit decreased to RMB 122.3 million in 2025 from RMB 179.481 million in 2024, reflecting a decline of 31.8%[21]. - Net profit for the year was RMB 135.253 million, down 29.7% from RMB 192.522 million in the previous year[21]. - Basic earnings per share for 2025 were RMB 6.25, a decrease of 36.4% compared to RMB 9.77 in 2024[22]. - The company reported a net profit attributable to owners of RMB 94,374,000 for 2025, a decline of 37.5% from RMB 150,780,000 in 2024[57]. - Adjusted net profit (non-HKFRS) decreased by 15.4% from RMB 233.5 million to RMB 197.6 million[92]. Revenue Breakdown - The blood purification business segment achieved a revenue of RMB 611.8 million for the year ending December 31, 2025, representing a 26.9% increase year-on-year, accounting for 74.3% of the group's total revenue during the reporting period[11]. - The infusion device business generated revenue of RMB 207.6 million, a decrease of 27.6% year-on-year, accounting for 25.2% of total revenue[9]. - The regenerative medical biomaterials segment recorded a revenue of RMB 4.1 million during the reporting period, with a focus on expanding sales and promoting innovative products[12]. - Revenue from the blood purification business rose by 26.9% to approximately RMB 611.8 million in 2025, compared to approximately RMB 482.3 million in 2024, due to increased market demand and expanded sales network[74]. - Revenue from the infusion device business decreased by 27.6% to approximately RMB 207.6 million in 2025, attributed to the implementation of centralized procurement policies[75]. Operational Efficiency and Strategy - The company is focusing on high-growth and high-margin medical device markets, enhancing R&D and product development capabilities[8]. - The company aims to optimize production processes and improve operational efficiency to address market challenges and expand its product portfolio[9]. - The group aims to strengthen its leading position in the medical device industry by focusing on cost reduction, efficiency improvement, and quality management[13]. - Continuous investment in R&D and innovation is emphasized as a cornerstone for sustainable development in the medical device sector[14]. - The company plans to submit registration applications for new products in the blood purification field, including a non-compliant PTA drug balloon catheter for treating vascular access issues in dialysis patients in the first half of 2026[15]. Market and Customer Insights - The number of ESRD patients requiring dialysis treatment is expected to continue increasing due to aging population and rising chronic kidney disease rates, leading to a higher treatment penetration rate in China[10]. - The group successfully won bids for blood dialysis products in 23 provinces and regions in China, indicating a stable procurement volume despite price pressure from bulk purchasing policies[11]. - The company has not identified any single customer contributing 10% or more to total revenue for the years ending December 31, 2025, and 2024, indicating a diversified customer base[45]. Shareholder Returns and Dividends - The company proposed a final dividend of HKD 0.02 per share, totaling HKD 0.064 per share for the year 2025[5]. - The company declared an interim dividend of HKD 0.044 per share for 2025, totaling approximately HKD 64,763,000, compared to HKD 67,713,000 in 2024[55]. - The proposed final dividend for the year ending December 31, 2025, is HKD 0.02 per share, down from HKD 0.053 per share in 2024, reflecting a decrease in shareholder returns[123]. Financial Position and Assets - Total assets as of December 31, 2025, amounted to RMB 5.235 billion, a slight increase from RMB 5.161 billion in 2024[23]. - The company’s cash and cash equivalents increased to RMB 1.803 billion in 2025 from RMB 1.682 billion in 2024, showing a growth of 7.2%[23]. - The company’s non-current financial assets increased to approximately RMB 70.7 million as of December 31, 2025, from RMB 46.5 million as of December 31, 2024, primarily due to an increase in fair value from investments[104]. - The company’s property, plant, and equipment amounted to approximately RMB 905.0 million as of December 31, 2025, an increase of approximately RMB 13.3 million from RMB 891.7 million as of December 31, 2024[100]. - Total equity as of December 31, 2025, was RMB 4,853,733,000, compared to RMB 4,803,368,000 in 2024, indicating a growth of approximately 1%[110]. Employee and Workforce - The company employed approximately 1,477 employees as of December 31, 2025, an increase from 1,415 employees in 2024, indicating growth in workforce[117]. - Total employee costs increased to RMB 194,681,000 in 2025, up 14.5% from RMB 170,011,000 in 2024[48]. Research and Development - Research and development expenses for 2025 amounted to RMB 63,413,000, an increase of 6.0% from RMB 59,703,000 in 2024[48]. - Research and development expenses rose by 9.7% to approximately RMB 48.4 million in 2025, primarily due to increased investment in blood purification projects[83]. Governance and Compliance - The company has adopted the corporate governance code as per the Listing Rules Appendix C1, ensuring compliance with relevant provisions[125]. - The board believes that consolidating the roles of Chairman and CEO under the same individual enhances leadership stability and aligns with the company's best interests[125]. - The audit committee has reviewed the consolidated financial information for the year ending December 31, 2025, discussing risk management and internal controls[128]. - The independent auditor confirmed that the figures in the performance announcement align with the consolidated financial statements for the year ending December 31, 2025[129].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失 承擔任何責任。 亞 東 Yadong Group Holdings Limited 亞 東 集 團 控 股 有 限 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：1795） 截至2025年12月31日止年度 全年業績公告 財務摘要 – 1 – . 收益由截至2024年12月31日止年度約人民幣1,078.6百萬元略微下降約人民幣5.1百萬 元或約0.5%至截至2025年12月31日止年度約人民幣1,073.5百萬元。 . 毛利由截至2024年12月31日止年度約人民幣136.5百萬元增加約人民幣8.1百萬元或約 5.9%至截至2025年12月31日止年度約人民幣144.6百萬元。 . 毛 利 率 由 截 至 2024 年 12 月 31 日 止 年 度 約 12.7% 增 加 至 截 至 2025 年 12 月 31 日 止 年 度 約 13.5%。 . 溢利由截至2024年12月31日止年度約人民幣37.0百 ...

財務摘要 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會對本公告的全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 山東天岳先進科技股份有限公司 SICC CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2631） 截至2025年12月31日止年度的業績公告 山東天岳先進科技股份有限公司（「公司」或「本公司」）董事（「董事」）會（「董事 會」）謹此宣佈本公司及其附屬公司（「集團、本集團」）截至2025年12月31日止年 度（「報告期」）的經審計綜合業績，以及截至2024年12月31日止年度經審計的比 較數據。 – 1 – ‧ 於報告期內，本集團實現總收入約為人民幣1,464.9百萬元，較2024年約 人民幣1,768.1百萬元減少17.1%； ‧ 於報告期內，本集團的研發開支約為人民幣165.8百萬元，較2024年約人 民幣141.8百萬元增加16.9%； ‧ 於報告期內，本集團的毛利約為人民幣141.8百萬元，較2024年約人民幣 435.5百萬元減少67.4%。截至2025年 ...